Saturday, July 25, 2026

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Pharma clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Intelligence · Clinical Programs

Teva Pharma projects

7 ClinicalTrials.gov programs sponsored by Teva Pharma.

Teva Pharma has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. TV-44749

    Teva Pharma GmbH

    Schizophrenia

    phase 3 small molecule completed

    3 trials
  2. Fremanezumab

    Teva Pharma GmbH

    Fibromyalgia

    phase 2 small molecule terminated

    1 trial
  3. Oral CEP-701

    Teva Pharma GmbH

    Myeloma

    phase 2 small molecule terminated

    1 trial
  4. Talampanel

    Teva Pharma GmbH

    ALS

    phase 2 small molecule completed

    1 trial
  5. armodafinil

    Teva Pharma GmbH

    Schizophrenia

    phase 2 small molecule completed

    2 trials
  6. TEV-53408

    Teva Pharma GmbH

    Vitiligo

    phase 1 small molecule active

    1 trial
  7. TL011

    Teva Pharma GmbH

    DLBCL

    phase 1 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Teva Pharma have?

7 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.